SANTAVACTM: Summary of Research and Development

Lokhov, Petr G.; Mkrtichyan, Mikayel; Mamikonyan, Grigor; Balashova, Elena E.

doi:10.3390/vaccines7040186

Cited by 7 publications

(8 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent review discusses the application of technology in the development of a variety of cancer vaccines based on the antigenic essence of cells [ 47 ]. The list of cancer vaccines developed using CPF is still limited by the antiangiogenic vaccine [ 48 ]. This is due to the fact that the CPF test is a relatively new direction in the field of cancer vaccines, which inspired the writing of this analytical review.…”

Section: Background Of Cell Proteomic Footprintingmentioning

confidence: 99%

Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines

et al. 2023

View full text Add to dashboard Cite

In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomic footprinting. The molecular phenotype of cells is highly variable, and their antigenic profile is affected by many factors, including cell isolation from the tissue, cell cultivation conditions, and storage procedures. This makes the therapeutic properties of cells, including those used in vaccines, unpredictable. Cell proteomic footprinting makes it possible to obtain controlled cell products. Namely, this technology facilitates the cell authentication and quality control of cells regarding their molecular phenotype, which is directly connected with the antigenic properties of cell products. Protocols for cell proteomic footprinting with their crucial moments, footprint processing, and recommendations for the implementation of this technology are described in this paper. The provided footprints in this paper and program source code for their processing contribute to the fast implementation of this technology in the development and manufacturing of cell-based immunotherapeutics.

show abstract

Section: Background Of Cell Proteomic Footprintingmentioning

confidence: 99%

Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The mechanism of action of SANTAVAC is based on EC heterogeneity and consists of the use of peptide profiles (essence code), which is similar to the surface antigens of tumor vessels, that allows targeted destruction of tumor vessels by vaccination. The use of proteomic footprinting and cytotoxicity assays to develop such essence compositions is described in detail in several publications ( Figure 6 a) [ 74 , 75 , 76 , 77 ]. The HMEC model made it possible to purposefully change the profile of surface antigens and obtain antigenic essence from them, demonstrating in vitro the high efficiency of the essence in comparison with other cellular preparations [ 75 ].…”

Section: Antigenic Essence Productsmentioning

confidence: 99%

Antigenic Essence: Upgrade of Cellular Cancer Vaccines

Lokhov

Balashova

2021

Cancers

View full text Add to dashboard Cite

The development of anticancer immunotherapy is characterized by several approaches, the most recognized of which include cellular vaccines, tumor-associated antigens (TAAs), neoantigens, and chimeric antigen receptor T cells (CAR-T). This paper presents antigenic essence technology as an effective means for the production of new antigen compositions for anticancer vaccination. This technology is developed via proteomics, cell culture technology, and immunological assays. In terms of vaccine development, it does not fit into any of the above-noted approaches and can be considered a new direction. Here we review the development of this technology, its main characteristics, comparison with existing approaches, and the features that distinguish it as a novel approach to anticancer vaccination. This review will also highlight the benefits of this technology over other approaches, such as the ability to control composition, optimize immunogenicity and similarity to target cells, and evade major histocompatibility complex restriction. The first antigenic essence products, presented under the SANTAVAC brand, are also described.

show abstract

“…While most of the contributions to this Special Issue have focused on vaccines against pathogens, Lokhov et al reviewed the research work and developments achieved with SANTAVAC TM , an antigen composition under development using a strategy combining proteomics and cell culture technologies, envisaging the production of vaccines against several solid tumors [ 16 ]. The SANTAVAC TM vaccine was designed to target tumor vessels, and is expected to outperform the approved antiangiogenic drugs available on the market [ 16 ]. The research and development of vaccines against cancer is a relatively recent, but highly active research field, expected to contribute to the cure of various types of cancers in the near future.…”

mentioning

confidence: 99%

“…The research and development of vaccines against cancer is a relatively recent, but highly active research field, expected to contribute to the cure of various types of cancers in the near future. The review describes the progress achieved so far with SANTAVAC TM , and summarizes the promising results obtained in non-clinical studies [ 16 ]. The research and development phase of SANTAVAC has been concluded, and the vaccine is in the preclinical stages [ 16 ].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Omics and Bioinformatics Approaches to Identify Novel Antigens for Vaccine Investigation and Development

Leitão

Rodríguez-Ortega

2020

Vaccines

View full text Add to dashboard Cite

Despite the outstanding technological advances achieved in the last few decades, infectious diseases remain a major societal challenge. From the variolation carried out in ancient China during the 15th century to the more advanced RNA and DNA vaccines presently available, vaccines have been proven as highly effective therapeutic tools to combat various infectious diseases. Vaccine research and development is now empowered with recent advances in Omics sciences and the developments of powerful bioinformatics tools. This Special Issue has gathered a total of nine original papers, including seven research papers and two reviews, illustrating the use of Omics data and bioinformatics in the research, design and development of vaccines against pathogens and cancer. The integration of knowledge from Omics and Bioinformatics will certainly boost vaccine research and development, leading to novel therapeutic tools against new and old pathogens and cancer in the near future.

show abstract

SANTAVACTM: Summary of Research and Development

Cited by 7 publications

References 89 publications

Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines

Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines

Antigenic Essence: Upgrade of Cellular Cancer Vaccines

Omics and Bioinformatics Approaches to Identify Novel Antigens for Vaccine Investigation and Development

Contact Info

Product

Resources

About